Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Insights, Forecast to 2029

Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Insights, Forecast to 2029

Market Analysis and Insights: Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) estimated at US$ 139345 million in the year 2023, is projected to reach a revised size of US$ 217203 million by 2029, growing at a CAGR of 7.68% during the forecast period 2023-2029.

The US & Canada market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 37855 million in 2023 to reach $ 50454 million by 2029, at a CAGR of 4.9% during the forecast period of 2023 through 2029.

The China market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 17129 million in 2023 to reach $ 51175 million by 2029, at a CAGR of 20.01% during the forecast period of 2023 through 2029.

The Europe market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 28502 million in 2023 to reach $ 36462 million by 2029, at a CAGR of 4.19% during the forecast period of 2024 through 2029.

The global key companies of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, etc. In 2022, the global top five players had a share approximately 14.45% in terms of revenue.

Report Includes

This report presents an overview of global market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization)revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lonza, Catalent, Thermo Fisher Scientific, Aenova, Siegfried, Recipharm, Strides Pharma, Piramal, and Boehringer Ingelheim, etc.

By Company

Catalent

Thermo Fisher Scientific

Lonza

Siegfried

Recipharm

Boehringer Ingelheim

WuXi AppTech

WuXi Biologics

Fareva

Samsung Biologics

Aenova

Delpharm

Strides Pharma

Piramal

Famar

Curia

Jubilant

Vetter

AGC Pharma Chemicals

Asymchem

Porton

Eurofins

Ascendia Pharmaceuticals

Ardena

CPL

UPM Pharmaceuticals

FUJIFILM Diosynth Biotechnologies

Groupe Parima

TBD Pharmatech

Avid Bioservices

NextPharma

Alcami

Societal CDMO

MedPharm

Euroapi

BioVectra

Pfizer CentreOne

Fermion

Lundbeck

Segment by Type

API CDMO

FDF CDMO

Packaging CDMO

Clinical CDMO

Segment by Application

Pharmaceutical Company

Biotechnology Company

Others

By Region

North America

United States

Canada

Asia (Ex. China)

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

China

Europe

Germany

France

U.K.

Italy

Russia

Rest of Europe

Latin America, Middle East & Africa

Mexico

Brazil

Middle East

Africa

Other

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization)revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions